BioSpace News Archive

Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics.

HepaTx, a biotechnology company focused on cell therapy for liver diseases, is thrilled to announce the appointment of Dr. Mack C. Mitchell to its Clinical Advisory Board. With his extensive gastroenterology and clinical pharmacology expertise, Dr. Mitchell brings invaluable knowledge to the team.

Versiti, a national leader in blood health innovation, announced the acquisition of Quantigen, a specialty lab based in Fishers, Indiana.

Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023.

Prothena Corporation plc announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005 and will pay Prothena $55 million.

Crinetics Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc.

Iovance Biotherapeutics, Inc. announced that it intends to offer and sell $150 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease, with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees.

Acerus Pharmaceuticals Corporation announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act and its previously announced sale and investment solicitation process, the Company completed the previously announced transactions with First Generation Capital Inc. as successful bidder under the SISP.

Zhejiang Doer Biologics Co., Ltd., a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announced that it has entered into a license agreement with BioNTech SE.